Skip to search formSkip to main contentSkip to account menu

ilmofosine

Known as: SH-MM-lysolecithin, 1-hexadecylmercapto-2-methoxymethyl-3-propylphosphoric acid monocholine ester, 1-mercaptohexadecyl-2-methoxymethyl-syn-glycero-3-phosphocholine 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Antineoplastic AgentsPhospholipid Ethers

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy.
2004
2004
Phase I and Pharmacokinetic Study of the Cytotoxic Ether Lipid Ilmofosine Administered by Weekly Two-Hour Infusion in Patients with Advanced Solid Tumors
Purpose: A Phase I trial was performed to determine the dose-limiting toxicity and maximum tolerated dose, and to describe the… 
2004
2004
A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma
SummaryWe have conducted a study of ilmofosine (1-hexadecylthio; 2-methoxyethyl-rac-glycero-3-phosphocho-line) in non-small cell… 
2004
2004
Phase I trial of ilmofosine as a 24 hour infusion weekly
Ilmofosine, an ether lipid derivative of lysophosphatidylcholine has antineoplastic activityin vitro andin vivo. Maximum efficacy… 
Highly Cited
1999
Highly Cited
1999
Induction of apoptosis in human mitogen‐activated peripheral blood T‐lymphocytes by the ether phospholipid ET‐18‐OCH3: Involvement of the Fas receptor/ligand system
Activated T‐cells constitute a target for treatment of autoimmune diseases. We have found that the antitumour ether phospholipid… 
1998
1998
Influence of probes for calcium-calmodulin and protein kinase C signalling on the plasma membrane Ca2+-ATPase activity of rat synaptosomes and leukocyte membranes.
1997
1997
Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440).
The thioether phospholipid ilmofosine (BM 41 440) is a new anti-cancer drug presently undergoing phase II clinical trials… 
1996
1996
Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB.
1994
1994
The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents.
The thioether phospholipid derivative ilmofosine (BM41440), a selective inhibitor of protein kinase C, is a new anticancer drug… 
1992
1992
Preclinical activity of ilmofosine against human tumor colony forming units in vitro
Ilmofosine (BM 41.440, 1-hexadecylthio-2-methoxymethyl-rac-glycero-3-phosphocholine) is a synthetic alkyl lysophospholipid analog… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)